Capricor Therapeutics CAPR
NASDAQ CAPR
$9.69 +1.12 (+13.07%)
As of: Sep 30, 2026 · 10:25 AM EDT

Capricor Therapeutics (CAPR) Short term Debt (2017)

Updated

Capricor Therapeutics (CAPR) reported Short term Debt of $14.16 million for Q3 2017, unchanged from the prior quarter.

Analysis

Capricor Therapeutics (CAPR) Short term Debt (2017) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn
10 Capricor Therapeutics 506.13 Mn 506.13 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2017 14.16 Mn
Jun 30, 2017 14.16 Mn
API Access

Capricor Therapeutics Short term Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt&ticker=CAPR&period=max&api_key=YOUR_API_KEY